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Background: There are potential conﬂicts between authorities and companies to fund
new premium priced drugs especially where there are safety and/or budget concerns.
Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with
non-valvular atrial ﬁbrillation (AF), exempliﬁes this issue. Whilst new effective treatments
are needed, there are issues in the elderly with dabigatran due to variable drug concen-
trations, no known antidote and dependence on renal elimination. Published studies have
shown dabigatran to be cost-effective but there are budget concerns given the prevalence
of AF. There are also issues with potentially re-designing anticoagulant services. This has
resulted in activities across countries to better manage its use.
Objective: To (i) review authority activities in over 30 countries and regions, (ii) use the
ﬁndings to develop new models to better manage the entry of new drugs, and (iii) review
the implications for all major stakeholder groups.
Methodology: Descriptive review and appraisal of activities regarding dabigatran and the
development of guidance for groups through an iterative process.
Results: There has been a plethora of activities among authorities to manage the pre-
scribing of dabigatran including extensive pre-launch activities, risk sharing arrangements,
prescribing restrictions, and monitoring of prescribing post-launch. Reimbursement has
been denied in some countries due to concerns with its budget impact and/or excessive
bleeding. Development of a new model and future guidance is proposed to better manage
the entry of new drugs, centering on three pillars of pre-, peri-, and post-launch activities.
Conclusion: Models for introducing new drugs are essential to optimize their prescribing
especially where there are concerns. Without such models, new drugs may be withdrawn
prematurely and/or struggle for funding.
Keywords: critical drug evaluation, dabigatran, demand-side measures, drug and therapeutics committees,
managed introduction new medicines, pharmacovigilance, registries, risk sharing
BACKGROUND
New medicines are of real value to patients when they improve
their health either because they are more effective, have less
side-effects, or are easier to administer than current standards.
European health authorities also wish new drugs to be cost-
effective (Garattini et al., 2008; Godman et al., 2008, 2009c, 2012d;
Wettermark et al., 2008, 2010a; Coma et al., 2009; Sermet et al.,
2010; Garuoliene et al.,2011b;Voncina andStrizrep,2011;Voncˇina
et al., 2011; Cheema et al., 2012; Markovic-Pekovic et al., 2012).
Continued pressure on resources is already resulting in some
countries unable to fund new premium priced drugs (Garuoliene
et al., 2011a,b; Godman et al., 2011c, 2012b; Taylor, 2011), with
the number of countries likely to increase with new drugs now
being launched at US$300,000 (€228,000) per patient per year
or more (Kaiser, 2012). Premium prices are of concern among
authorities struggling to maintain, and potentially incompati-
ble with, the European ideals of comprehensive and equitable
healthcare (Garattini et al., 2008; Adamski et al., 2010; Godman
et al., 2012b).
This may result in conﬂicts between authorities and pharma-
ceutical companies with the latter keen to re-coup the considerable
monies spent on research and development as soon as possi-
ble through rapid reimbursement (DiMasi and Grabowski, 2007;
Abraham, 2008; Jaroslawski and Toumi, 2011; Persson et al., 2012)
as well as maintain proﬁtability with established products (Shuch-
man, 2006; Abraham, 2008; Godman et al., 2010, 2011b, 2012b;
Voncˇina et al., 2011; Baumgärtel et al., 2012; Jackevicius et al.,
2012). However, this can be at oddswith the aims of health author-
ities and health insurance companies struggling to meet European
ideals within available resources (Shuchman, 2006; Abraham,
2008; Garattini et al., 2008; Godman et al., 2010, 2011b, 2012b;
Sermet et al., 2010; Garuoliene et al., 2011b; Voncina and Strizrep,
2011;Voncˇina et al., 2011; Baumgärtel et al., 2012; Ozieran´ski et al.,
2012). Marketing activities are seen as important by companies
to achieve their aims in an increasingly competitive environment
(Civaner, 2012); but these can involve considerable spending. Pub-
lished studies suggest marketing costs can be as high as one-third
of a company’s income (Civaner, 2012), with companies spending
US$53bn (€40.2) in the US alone in 2004 marketing to physi-
cians (Lexchin and Kohler, 2011; Godman et al., 2012b; Godman
and Gustafsson, 2013). In addition, there have been concerns with
aggressive lobbying and other indirect strategies by some compa-
nies (Mello et al., 2012; Ozieran´ski et al., 2012), as well as with
some of the marketing (Department of Justice, 2010; Grifﬁn and
Segal, 2010; Lexchin and Kohler, 2011; Fisk et al., 2012; Davies
and Abraham, 2013) and other activities (Jackevicius et al., 2012;
Baumgärtel et al., 2012; Ozieran´ski et al., 2012; Davies and Abra-
ham, 2013) to achieve their aims. This is despite the imposition of
multi-million dollar ﬁnes (Davies and Abraham, 2013).
These conﬂicts can be greater when there are safety concerns
with new drugs, and they are subsequently prescribed in a wider
population than studied in randomized clinical trials. Typically
Phase III clinical trials are conducted under ideal and highly con-
trolled conditions to seek high internal validity to maximize the
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chance of demonstrating clinical beneﬁt (Fritz and Cleland, 2003).
However, this may lead to substantial differences from their sub-
sequent use in clinical practice. Typically Phase III clinical trials
do not include treatment preferences and/or multimodal treat-
ment programs (Wells, 1999; Guthrie, 2000; Fritz and Cleland,
2003). Phase III clinical trials may also include a placebo group as
a comparator in order to isolate the effects of a particular inter-
vention (Fritz and Cleland, 2003). These situations can lead to
concerns with the generalizability of the ﬁndings when new drugs
are being considered as an alternative to current treatments, espe-
cially once prescribed in patients with greater co-morbidities than
those enrolled into Phase III clinical trials.
For example, both cerivastatin and mibefradil had favorable
beneﬁt–risk proﬁles at market authorization, but their use in
clinical practice, coupled with physicians ignoring recommended
guidance, caused their withdrawal from the market (Friedman
et al., 1999; Eichler et al., 2011). Previously in the 1980s zimelidine,
the ﬁrst selective serotonin re-uptake inhibitor, was withdrawn
from the market due to hypersensitivity reactions and febrile
reactions in connection to liver function disturbances, which
later evolved into Guillain–Barré syndrome (GBS; Carlson, 1999,
2000). This withdrawal might have been avoided if zimelidine
had been introduced in a stepwise fashion, as there was an aver-
age increase of GBS-risk of 25-fold among patients receiving
zimelidine compared with the natural incidence of the disorder
(Fagius et al., 1985).
Rofecoxib was also withdrawn following growing evidence of
increased cardiovascular events such as heart attacks and stroke
with long-term treatment (Merck, 2004; MHRA UK, 2004). Rofe-
coxib was seen as the most selective COX-II inhibitor among
the ﬁrst generation of this class with minimal COX-I activity
(Davies and Jamali, 2004). Whilst this reduces gastrointestinal
(GI) side-effects, this also reduced the cardioprotective effect of
COX-I inhibitors that is similar to low-dose aspirin (Davies and
Jamali, 2004; Bresalier et al., 2005). This protective effect of COX-I
inhibitors led to a reduction in the risk of thrombotic cardiovascu-
lar events in patients treated with naproxen compared to rofecoxib
(Reicin et al., 2001; Weir et al., 2003; Davies and Jamali, 2004),
documented in the VIGOR study (Bombardier et al., 2000). The
study speciﬁcally excluded patients who were taking concomitant
aspirin or other antiplatelet drugs such as those with a recent his-
tory of myocardial infarction or stroke (Bombardier et al., 2000;
Merck, 2002). The ﬁndings led to a caution being added to the
product label in May 2002 in patients with a medical history of
ischemic heart disease (FDA, 2002; Merck, 2002). The concerns
with increased cardiovascular events associated with long-term
rofecoxib therapy also led to the instigation of the APPROVe study
(Bresalier et al., 2005). The ﬁndings of increased cardiovascular
risk with rofecoxib (Bresalier et al., 2005) subsequently led to its
withdrawal (Davies and Jamali, 2004; Merck, 2004; MHRA UK,
2004). There are ongoing debates whether the withdrawal of rofe-
coxib may have been avoided if there had not been appreciable
marketing activities, including considerable direct to consumer
advertising in the US, promoting the safety of COX-II inhibitors
(Calfee and Pinell, 2005).
Natalizumab was withdrawn soon after its launch despite
improved effectiveness in patients with relapsing multiple
sclerosis. This was due to the development of progressive multi-
focal leukoencephalopathy (PML) in some patients (Kappos et al.,
2011; Keegan, 2011). However, it was re-launched some 2 years
later in Europe, but under strict prescribing regulations and with
the instigation of research programs to clarify the beneﬁt:risk
ratios (Kappos et al., 2011; Keegan, 2011). More recently, rimon-
abant has been withdrawn from the market. Patients prescribed
rimonabant experienced a higher incidence of anxiety, depres-
sion, and insomnia (Moreira et al., 2009; O’Shaughnessy, 2009;
Ioannides-Demos et al., 2011). This led to advice that patients
prescribed rimonabant should be investigated ﬁrst for psychiatric
illness and that rimonabant should not be prescribed in patients
with mental illness (Moreira et al., 2009; O’Shaughnessy, 2009;
Ioannides-Demos et al., 2011). However, this advice was some-
times ignored leading to its withdrawal due to increased risk of
depression and suicidal ideation (European Medicines Agency
[EMA], 2009; Godman et al., 2009c; Dietrich and Horvath, 2012;
Wong et al., 2012). It may be that greater knowledge of the role
of the hypothalamus in enabling the central nervous system to
adapt to the changing environment could facilitate the discovery
of new agents that are more effective and have a more acceptable
beneﬁt–risk proﬁle (Wong et al., 2012). However, this remains to
be seen.
New oral anticoagulants (NOACs) illustrate some of these ten-
sions as they show promise in the prevention of stroke in patients
with atrial ﬁbrillation (AF), offering an alternative to warfarin
without the need for INR (International Normalized Ratio) moni-
toring (Baetz and Spinler, 2008; Connolly et al., 2009; Malmström,
2009; Pink et al., 2011; Scottish Medicines Consortium, 2011;
Banerjee et al., 2012; Godman et al., 2012d; Kansal et al., 2012;
Mannuci et al., 2012; National Institute for Health and Clinical
Excellence, 2012; Davidson et al., 2013; Joppi et al., 2013; Marshall
et al., 2013; Rodriguez et al., 2013). This is in addition to venous
thromboembolism prophylaxis for patients undergoing hip and
knee surgery, and in the treatment of acute deep vein throm-
bosis and pulmonary embolism (Marshall et al., 2013). However,
there are safety concerns especially in the elderly (Malmström,
2009; Pink et al., 2011; Godman et al., 2012d; Mannuci et al., 2012;
Stollberger and Finsterer, 2013) in addition to potential compli-
ance (Marshall et al., 2013; Rodriguez et al., 2013) and storage
issues (Stollberger and Finsterer, 2013).
Atrial ﬁbrillation is the most common clinically signiﬁcant car-
diac arrhythmia with an estimated prevalence of 1–2% of the
population (Marshall et al., 2013). One in four adults over the
age of 40 is likely to develop AF in their lifetime, higher in those
aged over 80 (Lloyd-Jones et al., 2004; Stewart et al., 2004; Camm
et al., 2010; Pink et al., 2011; Mannuci et al., 2012; Davidson et al.,
2013). Current estimates suggest there are 4.5 million people in
Europe with AF and 3.03 million in the US (Marshall et al., 2013),
with the prevalence of AF likely to double in the next 50 years
with ageing populations (Go et al., 2001; Stewart et al., 2001, 2004;
Lloyd-Jones et al., 2004; Luengo-Fernandez et al., 2006; Kirchhof
et al., 2007; Connolly et al., 2009; Camm et al., 2010; Pink et al.,
2011; Marshall et al., 2013). New drugs are needed since patients
withAFhave a ﬁvefold increased risk of cardioembolic stroke com-
paredwith those in sinus rhythm (Stewart et al., 2004; Cammet al.,
2010; Pink et al., 2011), with a cardioembolic stroke resulting in
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approximately 20% of patients dying in the acute phase and 60%
developing severe disability (Mannuci et al., 2012). Incurred costs
also tend to be higher in stroke patientswithAF,with those patients
who survive left more disabled by their stroke and more likely to
have a recurrence than those with other causes of stroke (Luengo-
Fernandez et al., 2006; Camm et al., 2010; Kansal et al., 2012).
Initial incurred secondary care costs averaged GB£9667/patient
(2005 costs) in patients with AF compared with an average of
GB£5824 in other stroke patients (Luengo-Fernandez et al., 2006).
As a consequence, the risk of death from AF related strokes is
doubled compared with other forms of stroke, and the overall
cost of care increased 1.5-fold (Kirchhof et al., 2007; Camm et al.,
2010; Scottish Medicines Consortium, 2011; National Institute
for Health and Clinical Excellence, 2012). Anticoagulant therapy
with vitamin K antagonists (VKAs) can reduce by at least 60% the
risk of stroke (Camm et al., 2010; Mannuci et al., 2012). How-
ever, there are concerns with warfarin due to the potential of
bleeding, the need to tailor doses to the individual with too high
a dose potentially causing serious complications and too low a
dose losing protection, and the difﬁculties with maintaining some
patients within INRs (Pink et al., 2011; Mannuci et al., 2012;
Marshall et al., 2013).
Dabigatran received EU marketing authorization in August
2011 (Boehringer Ingelheim, 2011a; Marshall et al., 2013) for
the prevention of stroke and systemic embolism/clot formation
in adult patients with non-valvular AF with one or more of the
following risk factors:
• Previous stroke, transient ischemic attack, or systemic
embolism/clot formation
• Left ventricular ejection fraction <40%
• Symptomatic heart failure > New York Heart Association
(NYHA) Class 2
• Age> 75 years
• Age > 65 years in combination with additional vascular risk,
i.e., patients with diabetes mellitus, coronary artery disease, or
arterial hypertension
Published studies showed a 9% reduction in the prevention of
stroke or systemic embolism with dabigatran 110 mg twice daily
and 34% for the 150 mg twice daily (Horsley, 2010; Mannuci
et al., 2012; Davidson et al., 2013; Marshall et al., 2013). Over-
all mortality was also reduced by 12% for the highest dose of
dabigatran, which reached statistical signiﬁcance (Horsley, 2010;
Mannuci et al., 2012). There was also an appreciable and consis-
tent reduction in the risk of hemorrhagic stroke ranging from 69
to 74% depending on the dose of dabigatran (Horsley, 2010; Pink
et al., 2011; Mannuci et al., 2012), with the 150 mg twice daily
dose of dabigatran also providing a statistical signiﬁcant reduc-
tion in ischemic stroke (24% risk reduction; Horsley, 2010; Pink
et al., 2011; Mannuci et al., 2012). Dabigatran could also poten-
tially require no monitoring compared with warfarin (Pink et al.,
2011; Godman et al., 2012d; Mannuci et al., 2012; Marshall et al.,
2013). As a result, dabigatran has the potential to be an important
new treatment, especially where regular monitoring with warfarin
is problematic or where there are adverse events or other patient
issues with warfarin.
These improvements, coupled with potential savings with
dabigatran with the opportunity to reduce patient monitor-
ing, resulted in incremental cost-effectiveness ratios (ICERs) of
GB£4831 (€5560)/quality adjusted life year (QALY) in patients
under 80 versus warfarin and GB£7090 (€8150) above 80 (Kansal
et al., 2012). A similar study in Sweden estimated the cost/QALY
gained for dabigatran versus warfarin as €7742, increasing to
€12,449 in patients who were well controlled with warfarin
(Davidson et al., 2013). Other authors have published higher
ICERs, i.e., GB£23,082 (€26,700)/QALY for high dose dabi-
gatran versus warfarin (Pink et al., 2011; Scottish Medicines
Consortium, 2011; Marshall et al., 2013). The manufacturer’s
submission to the Scottish Medicines Consortium (SMC) sug-
gested a cost/QALY of GB£6986 (€8030) versus warfarin. This
estimate was based on the sequencing of dabigatran, start-
ing with 150 mg twice daily for patients under the age of 80
who were subsequently switched to 110 mg twice daily when
they reached 80 years (Scottish Medicines Consortium, 2011).
The ICER increased to GB£13,347 (€15,350) when the model
was adjusted to lower the potential savings from reduced INR
monitoring to a more appropriate ﬁgure (Scottish Medicines
Consortium, 2011; Marshall et al., 2013). The Evidence Review
Group (ERG) of the National Institute for Health and Clini-
cal Excellence (NICE) also had concerns with the model pro-
vided by the manufacturer and the cost of anticoagulation
therapy (National Institute for Health and Clinical Excellence,
2012; Marshall et al., 2013). Under different assumptions, the
ERG believed the base case ICER for dabigatran 150 mg twice
daily increased from GB£6264 (€7200) to GB£24,173–29,131
(€27,790–33,490)/QALY (National Institute for Health and Clin-
ical Excellence, 2012). This was due to two main weaknesses in
the submitted model (National Institute for Health and Clini-
cal Excellence, 2012). These included the lack of any potential
switching of treatment from dabigatran back to warfarin as well
as an overstatement of the costs of monitoring patients pre-
scribed warfarin in practice (National Institute for Health and
Clinical Excellence, 2012). There were also concerns that patient
heterogeneity would be greater in practice than allowed for in
the submitted models (National Institute for Health and Clinical
Excellence, 2012; Marshall et al., 2013). However, both organi-
zations recommended dabigatran as an alternative to warfarin
in patients who meet the criteria outlined in the marketing
authorization (Scottish Medicines Consortium, 2011; National
Institute for Health and Clinical Excellence, 2012; Marshall et al.,
2013), with NICE also recommending that dabigatran should
only be prescribed after an informed discussion between clin-
icians and patients (National Institute for Health and Clinical
Excellence, 2012). The National Centre for Pharmacoeconomics
(NCPE) in Ireland recently concluded that the ICER for dabi-
gatran versus warfarin was €6311/QALY in patients under 80
years and €20,654/QALY in patients 80 years or older. Extracra-
nial hemorrhage was an important cost driver (versus war-
farin in those 80 years and over) and disability costs were
important across all comparisons (National Centre for Pharma-
coeconomics, 2011).
However, there have been concerns with the rapid intro-
duction of dabigatran, which led to an appreciable number of
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serious adverse events with the ﬁrst 12 weeks of availability in
the US (Institute for Safe Medication Practices, 2011). These
were principally serious bleeding events or blood clots in the
elderly (Institute for Safe Medication Practices, 2011). These con-
cerns and others led the FDA to explore correlating reductions
in stroke events with increasing plasma correlations alongside
bleeding event rates (Thompson, 2010), with the guidance avail-
able when dabigatran was launched in Europe. In addition,
re-examining and comparing the bleeding rates with warfarin
and dabigatran (Southworth et al., 2013). These concerns have
arisen due to dabigatran’s low mean oral bioavailability, consid-
erable variation in plasma drug concentrations, and the complete
dependence on renal elimination of the active metabolite (Stang-
ier et al., 2008; Stangier and Clemens, 2009; Thompson, 2010;
Liesenfeld et al., 2011; Douxﬁls et al., 2012; Huisman et al., 2012;
Mannuci et al., 2012; Ten Cate, 2012). Consequently, any accu-
mulation of dabigatran in patients with reduced renal function
will increase their risk of excessive bleeding (Malmström, 2009;
Legrand et al., 2011; Pink et al., 2011; Garber et al., 2012; Godman
et al., 2012d; Harper et al., 2012; Huisman et al., 2012; Man-
nuci et al., 2012; Ten Cate, 2012), complicated by no known
antidote (Rolfe et al., 2010; Institute for Safe Medication Prac-
tices, 2011; Pink et al., 2011; Godman et al., 2012d; Huisman
et al., 2012; Mannuci et al., 2012; Marshall et al., 2013). This is
important in this situation as patients in clinical practice are
likely to be more elderly, have greater co-morbidities, and have
reduced hepatic and renal functions, compared to the patients
in the clinical trials (Joppi et al., 2013). There are also concerns
with its budget impact given the growing prevalence of AF (Pink
et al., 2011; Godman et al., 2012d; Midlands Therapeutic Review
and Advisory Committee [MTRAC], 2012; Marshall et al., 2013).
A number of health authorities across Europe have recognized
these issues and initiated extensive pre- and peri-launch pro-
grams to educate physicians and the public regarding the optimal
use of dabigatran, especially in elderly patients with poor renal
function.
The principal objective of this paper is to review health
authority and health insurance company activities across Europe
pre-launch to post-launch of dabigatran for the prevention of
stroke as an exemplar for developing future models to better man-
age the entry of new premium priced drugs. Subsequently, to use
these strategies to suggest future activities that all key stakeholder
groups could undertake to reduce the likelihood of new drugs
being removed from the market place where there are concerns
with their use in a wider patient population. Finally, to suggest
activities that better manage expenditure on new drugs where
there are concerns with their budget impact. This is important
as concerns with the budget impact of new drugs are growing.
This especially given the number of new drugs in development
including new biological drugs (EvaluatePharma, 2012; Godman,
2013), which are now costing up to US$10,000–25,000 (€7580–
18,960) per patient per month (Selyukh, 2011; Yukhananov,
2011; Godman et al., 2012b; Kaiser, 2012; UK Medicines
Information, 2012; UKMi Medicines Information, 2013). This
potentially inhibits the ability of governments to continue to
provide equitable and comprehensive healthcare within current
budgets.
METHODOLOGY
A descriptive review of national, regional or local health authority,
health insurance companyorphysician association activities across
Europe regarding dabigatran up to and including the beginning of
2013 was conducted by one of the co-authors (Brian B. Godman).
This was undertaken by collating and appraising relevant pub-
lished papers and internal documents known to the co-authors
as well as any pertinent documents available on the internet.
Direct feedback was provided by the co-authors where there was
limited or no data available in a particular country. The infor-
mation provided by the co-authors was subsequently re-checked
(Brian B. Godman) to enhance its accuracy. In total, information
was collected from over 30 European countries and regions. We
have used this methodological approach in previous publications
involving health authority and health insurance company person-
nel when there has been a paucity of published data (Cheema et al.,
2012; Godman et al., 2011b,c, 2010, 2012a,b; Adamski et al., 2010;
Baumgärtel et al., 2012). The countries were chosen to provide
differences in geography, epidemiology, ﬁnancing of healthcare,
available resources for healthcare as well as different approaches to
the pricing and reimbursement of newdrugs (Godman et al., 2008,
2010, 2011b, 2012d; Wettermark et al., 2008, 2010a; Coma et al.,
2009; Sermet et al., 2010; Garuoliene et al., 2011a,b; Voncina and
Strizrep, 2011; Cheema et al., 2012; Markovic-Pekovic et al., 2012;
Godman and Gustafsson, 2013). This included both national and
regional authorities in some countries, recognizing ongoing bud-
get devolution, e.g., England, Scotland, Spain, and Sweden, as well
as differences with the organization and funding of anticoagulant
services.
Demand-side initiatives and reforms were collated under four
different activities named the four Es – Education, Engineering,
Economics, and Enforcement (Wettermark et al., 2009a) – to pro-
vide comparisons with measures used to improve the quality and
efﬁciency of the prescribing of existing drugs across Europe (God-
man et al., 2009b,c, 2010, 2011a,b, 2012b,c,f; Wettermark et al.,
2009a,b, 2010b; World Health Organisation, 2009; McGinn et al.,
2010; Gustafsson et al.,2011;Voncˇina et al.,2011; Baumgärtel et al.,
2012; Bennie et al., 2012; Kalaba et al., 2012; Markovic-Pekovic
et al., 2012; Medicine Balance [MEDICIJNBALANS], 2012; van
Woerkom et al., 2012); they include:
• Educational activities – these range from simple distribution
of printed material to intensive strategies including academic
detailing and monitoring of prescribing habits usually by pro-
fessional medical networks. Examples include local, regional,
and national formularies, guidance and guidelines including
those from Drug and Therapeutic Committees
• Engineering activities – organizational or managerial issues to
inﬂuence change, e.g., quality and efﬁciency prescribing targets
• Economic interventions – ﬁnancial incentives. These include
ﬁnancial incentives for physicians if they achieve agreed pre-
scribing targets in a class, devolution of drug budgets to local
GP groups combined with regular monitoring of prescribing
behavior, as well as ﬁnes for prescribing costs above agreed lim-
its. Initiatives also include patient co-payments, especially if
patients wish a more expensive product than the current ref-
erence priced product for the molecule (Anatomical Chemical
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Therapeutic – ATC – Level 5) or the class/group (ATC Level 3
or 4)
• Enforcement – regulations by law such as compulsory Interna-
tional Non-proprietary Name (INN) prescribing, compulsory
generic substitution, or prescribing restrictions such as those
instigated for patented statins in Austria, Finland, and Nor-
way and the angiotensin receptor blockers (ARBs) in Austria,
Croatia, Lithuania, the Republic of Srpska, and Sweden
No attempt has been made to critique the initiatives, including
comparing and contrasting the potential inﬂuence of the multiple
initiatives across the countries and regions to provide future guid-
ance. This is because thiswould require a thorough analysis of drug
utilization patterns alongside associated health policies (Coma
et al., 2009; Godman et al., 2009b, 2010, 2011a,b, 2012c; Wetter-
mark et al., 2009b, 2010b; McGinn et al., 2010; Garuoliene et al.,
2011b; Voncˇina et al., 2011; Bennie et al., 2012; Kalaba et al., 2012;
Markovic-Pekovic et al., 2012; vanWoerkom et al., 2012). This will
be undertaken in future research projects. However, documented
initiatives were used to derive suggested models and potential
guidance for all key topics and stakeholder groups to improve
the managed entry of new drugs in the future. Initial models and
draft guidancewere subsequently amended and reﬁned through an
iterative process. This involved several rounds with the co-authors
until all co-authors were satisﬁed and agreed with the proposed
new model and guidance provided.
RESULTS
HEALTH AUTHORITY AND HEALTH INSURANCE COMPANY ACTIVITIES
Table 1 summarizes some of the health authority/health insurance
company activities pre-, peri-, and post-launch up till the end of
2012. Unless stated, the indications are those contained in theEMA
marketing authorization (Boehringer Ingelheim, 2011a; European
MedicinesAgency [EMA], 2008; EMA,2012; Marshall et al., 2013).
Table A1 in the Appendix provides a comprehensive summary of
examples from regions and countries across Europe.
Similarly in Australia, the Department of Health and Ageing
in the Ministry of Health recently undertook a review of NOACs
in the management of stroke risk in patients with AF (Australian
Government Department of Health and Ageing, 2012). They rec-
ommended to the Pharmaceutical Beneﬁts Advisory Committee
(PBAC) the following based on their belief that the net overall
beneﬁt of NOACs in clinical practice, and the subsequent impact
on cost-effectiveness, is uncertain at this stage:
• Initiating amanaged entry scheme taking into account the iden-
tiﬁed uncertainties while acknowledging the clinical need for
effective alternatives to warfarin. This includes the entry price
that addresses the uncertainties
• New oral anticoagulants are only reimbursed in patients unable
to tolerate warfarin therapy and/or who are unable to obtain
satisfactory INR control despite speciﬁc measures. This would
require a deﬁnition of “satisfactory INR control” together with
potential price–volume arrangements that address the risk to
the Australian Government of use beyond such restrictions
This recommendation has resulted in PBAC undertaking
further analysis as it reviews its previous decisions (NPS
MEDICINEWISE, 2012).
PROPOSED MODEL AND ASSOCIATED ACTIVITIES
Figure 1 outlines the suggested new model to better manage the
entry of new drugs in the future. This is based on the extensive
knowledge and experience of the co-authors shared across health-
care institutions. This builds on the three pillars of pre, peri-,
and post-launch activities (Wettermark et al., 2010a; Godman
et al., 2012d).
This startswith horizon scanning activities pre-launch and con-
tinues to post-launch monitoring, benchmarking, and registries.
Potential activities for each stakeholder group are discussed later
in Table 4.
There has been a growth in risk sharing arrangements across
Europe as health authorities and health insurance companies
struggle to fund new premium priced products within avail-
able funds (Adamski et al., 2010; Godman, 2011; Jaroslawski
and Toumi, 2011; Klemp and Frønsdal, 2011; Cheema et al.,
2012; Hirschler, 2012; Jommi, 2012; Siviero et al., 2012; Vogler
et al., 2012). Risk sharing has previously been deﬁned as agree-
ments concluded by payers and pharmaceutical companies to
diminish the impact on the payer’s budget of new and exist-
ing medicines brought about by either the uncertainty of the
value of the medicine and/or the need to work within ﬁnite
budgets (Adamski et al., 2010; Godman, 2011). Consequently,
the agreement lies in setting the scope and realizing the mutual
obligations amongst both payers and pharmaceutical compa-
nies depending on the occurrence of an agreed condition –
the “risk,” which varies by situation (Adamski et al., 2010;
Godman, 2011).
In view of the concerns with some of these schemes, coupled
with the experiences with dabigatran across Europe (Table 1 and
Table A1 in the Appendix), national and regional health author-
ities and health insurance companies should consider a number
of key issues when appraising risk sharing schemes in the future
(Table 2). These considerations do not apply to price:volume
agreements, straight discounts or rebates, which are easier to
administer (Jaroslawski and Toumi, 2011).
Health authorities and health insurance companies also need
to consider a number of key issues before implementing patient
registries. Key considerations and issues are shown in Table 3.
Patient registries can subsequently be used to assess the effective-
ness, safety and cost-effectiveness of new treatments in routine
clinical care. The nature and extent of data collected will depend
on the objectives of any study.
Overall, there are a number of activities that each key stake-
holder group should consider pre-, peri-, andpost-launch to better
manage the entry of new drugs. This is especially important where
there are potential safety and/or resource issues (Table 4). These
build on the three pillars and a brief outline of activities discussed
in Figure 1.
EMA AND FDA ACTIVITIES
The low mean bioavailability of dabigatran (Douxﬁls et al., 2012;
Mannuci et al., 2012; Ten Cate, 2012), as well as studies demon-
strating considerable variation in plasma drug concentrations
in practice, led the FDA in 2010 to explore the relationship
between dabigatran concentrations in plasma and the risks of
suffering a stroke or major bleeding (Thompson, 2010; Ten
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Table 1 | Summary of key activities across Europe to improve the quality and efficiency of prescribing of dabigatran (Godman et al., 2008,
2009a,c, 2011a, 2012d; Holmström et al., 2009; Janusinfo, 2009, 2012a,b; KVH - Aktuell, 2010; Martikainen et al., 2010;Wettermark et al., 2010a,c;
Boehringer Ingelheim, 2011b; Gustafsson et al., 2011; Neue Arzneimittel, 2011; Stockholms läns landsting, 2011;Voncˇina et al., 2011; Keele
University School of Pharmacy, 2012; Medicin & Läkemedel, 2012; MidlandsTherapeutic Review andAdvisory Committee [MTRAC], 2012;
Östergötland, 2012; Persson et al., 2012; Davidson et al., 2013).
Timing Examples of activities among European countries and regions
Pre-launch
(principally
education)
Swedish counties:
(A) Östergötland County Council
• Update of the previous report on the prevalence of atrial ﬁbrillation in Östergötland
• Establishing a working party with broad representation from the departments of cardiology and internal medicine, primary health
care, representatives from the warfarin polyclinics, epidemiologist and health economists associated with the Drug and Therapeutics
Committee (DTC)
• Scientiﬁc publication of the cost-effectiveness model for dabigatran for the prevention of stroke based on Östergötland by the Centre
for Medical Technology Assessment, Linköping University, in collaboration with Östergötland County Council
• Consensus action plan agreed 12 months before dabigatran was registered for the prevention of stroke in patients with AF
• Recommendation from the DTC to classify dabigatran as a “focus-drug”, i.e., the prescribing unit will be responsible for the cost of
the drug. If however patients are entered into the County Council’s quality assessment program, the cost will be borne by the County
Council. Decision by the County Council to follow the recommendation of the DTC
• Resources for treating patients allocated in the 2011–2012 County Council drug budgets
• Communication plan implemented
(B) Stockholm County Council
• Systematic and long-term involvement of medical and scientiﬁc expertise in the development of guidelines and advise to patients and
prescribers through the Regional Drugs andTherapeutic Committee (DTC) and clinical pharmacologists
• Extensive pre-launch activities with key messages broadcasted both to the public and to prescribers through websites of the DTC as
well as the Swedish Medical Journal
• Appreciable number of pre-launch meetings and training sessions with all major physician groups around the key issues and concerns
with dabigatran as well as its likely place in care
• Production of educational folders regarding dabigatran, slide kits, published articles, and data on the Janus website as well as published
information for patients
• Forecasting the potential budget impact in 2011 and 2012 ahead of launch and monitoring this in practice
• Development of a laboratory method to monitor dabigatran in plasma with LC-MS/MS technology, and recommending sampling in the
introductory phase to build a knowledge database. This to be followed by more situation-based sampling to improve patient safety in
the future
Peri-launch
(principally
education)
(A) West Midlands (Region – England)
• Development of guidance stating that warfarin remains the ﬁrst-line option for anticoagulation in patients with AF at high risk of a stroke,
and primary care trusts (have been replaced by Clinical Commissioning Groups from April 1, 2013) should ensure optimal existing
warfarin therapy services – including access to INR clinics, use of computerized decision-support software, and access to drugs for
patients who are allergic to warfarin (the latter rare in practice)
• In addition in view of the considerable ﬁnancial implications, dabigatran treatment should only be prescribed for patients:
◦ with co-morbidities who are adherent to warfarin monitoring and lifestyle requirements but need frequent co-prescribed medications
that interact with warfarin and affect the patients’ time in the therapeutic range (TTR)
◦ who are adherent to monitoring and lifestyle requirements but whose TTR remains unacceptable despite attempts to optimize
treatment with warfarin (TTR rates should be set locally)
(B) Germany
• Physician Associations stressing when launched that the current knowledge regarding safety with dabigatran was insufﬁcient to answer
all questions, and physicians should be careful with prescribing particularly in the elderly
• The reporting of deaths from excessive bleeding further endorsed these concerns. As a result, limited prescribing in practice in
ambulatory care
(C) Slovenia
• Reimbursed in conjunction with a complex price:volume agreement
(Continued)
www.frontiersin.org May 2013 | Volume 4 | Article 39 | 7
“fphar-04-00039” — 2013/5/13 — 13:14 — page 8 — #8
Malmström et al. Dabigatran – a case history
Table 1 | Continued
Timing Examples of activities among European countries and regions
Post-launch
(principally
education
and enforce-
ment)
(A) Austria (enforcement)
• Ex ex-ante approval by the head physician of the patient’s social health insurance fund before reimbursement of dabigatran; otherwise
100% co-payment (mirroring other situations)
• Renal function has to be assessed and recorded prior to initiation of therapy with dabigatran through determining Creatinine-Clearance
(CrCl) levels to exclude patients with severe renal dysfunction (=CrCl < 30 ml/min). In addition during treatment, renal function has to
be monitored where a decline is envisaged, e.g., patients with hypovolemia, dehydration, and the use of speciﬁc additional medication,
and renal function has to be assessed at least once a year in patients aged 75 or older, and/or in patients with compromised renal
function
(B) Finland (enforcement)
• Reimbursement restricted to patients with risk factors where satisfactory control has not been reached with warfarin; alternatively,
warfarin cannot be prescribed due to side-effects or contra-indications
• Enforcement at the pharmacy with on average 16 days needed for requests to be centrally reviewed and authorized. Hundred percent
co-pay without authorization
(C) Slovenia
• Education of all involved specialists and primary care physicians on key safety aspects/adverse events with dabigatran
• Prescribing restrictions (Enforcement):
• Only reimbursed if initiated by an internist or neurologist and prescribed according to agreed indications, e.g., only reimbursed in
patients already on warfarin if they are unstable with TTR < 65
• Patients have to be followed in a tertiary or secondary care anticoagulation center. Patients can be followed in primary care but only
if authorized by the tertiary or secondary care center.
• Every patient has to be registered in a database and followed by the IT anticoagulation program
• Anticoagulation centers have to report once yearly to the tertiary center regarding the number of patients experiencing minor and
major bleeding, thromboembolic events, as well as any deaths from bleeding or thromboembolism with dabigatran
Table 2 | Key issues for health authorities and health insurance companies to consider when appraising risk sharing arrangements proposed by
pharmaceutical companies for new drugs.
Key issues regarding risk sharing arrangements
• Validity of the appropriateness of the arrangement(s) for the situation/circumstances in the country/region incorporating current or proposed service
delivery arrangements and involving the use of experts
• Speciﬁcity and transparency of the objectives and scope of the proposed scheme(s)
• Novelty of the new drug – including its envisaged health gain, assessment of the effectiveness of current treatments, priority of the disease area, and
the translational evidence base
• Proportion health authorities will end up funding of a new drug’s development costs through registries post-launch
• Data ownership – ideally, all key stakeholders should be involved in the development of any subsequent patient registries. In principal, these should be
funded by the manufacturer
• Feasibility of IT infrastructure already in place to collect data to monitor the agreement(s) in practice. Alternatively, if new structures are needed, their
development costs need to be considered alongside the ﬁnancial beneﬁts of any proposed risk sharing scheme
• Beneﬁcial impact on service delivery and/or safety of the new drug. This should be substantial but has been difﬁcult to prove in Phase III trials
• Administrative burden of any proposed risk sharing scheme in relation to the potential overall savings
• Likely patient concordance in practice, especially if this has not been fully considered in the proposed scheme(s)
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FIGURE 1 | Proposed model for optimizing the managed entry of new drugs across Europe incorporating national and regional stakeholder groups
where pertinent building on the example of dabigatran.
Cate, 2012). These publications also demonstrated it is impor-
tant to avoid too low or too high levels of dabigatran (Mismetti
and Laporte, 2010; Thompson, 2010). Consequently similar
to warfarin, certain patients on dabigatran and other NOACs
should be monitored to reduce potential side-effects (Mismetti
and Laporte, 2010; Douxﬁls et al., 2012; Mannuci et al., 2012;
Ten Cate, 2012).
The EMA in their Risk Minimization Plan for dabigatran issued
in 2011 also deﬁned a cut-off for the risk of bleeding with the
150 mg bid regimen of 200 ng/mL dabigatran in plasma at Ctrough
(Heidbüchel et al., 2011).
DISCUSSION
Dabigatran and the other NOACs are the result of a long search for
an alternative to warfarin to prevent strokes in patients with AF.
However, the weighing of the advantages and disadvantages asso-
ciated with dabigatran, especially in the elderly with poor renal
function, needs to be judged carefully and handled appropriately
alongside the additional acquisition costs of dabigatran. These
challenges led to an extensive range of activities among national
and regional health authorities, health insurance companies, and
physician associations across Europe pre-, peri-, and post-launch
to enhance its appropriate use (Table 1 and Table A1 in the
Appendix).
The main medical concerns were the risk of excessive bleeding
in elderly patients with AF with no known antidote, vari-
able plasma drug concentrations in practice exacerbated by low
bioavailability, and the dependence on renal elimination of the
active metabolite (Baetz and Spinler, 2008; Malmström, 2009;
Legrand et al., 2011; Liesenfeld et al., 2011; Banerjee et al., 2012;
Douxﬁls et al., 2012; Godman et al., 2012d; Harper et al., 2012;
Huisman et al., 2012; Mannuci et al., 2012; Ten Cate, 2012; Mar-
shall et al., 2013). Cases of major bleeding and deaths were seen
with dabigatran soon after its launch (Malmström, 2009; Insti-
tute for Safe Medication Practices, 2011; EMA, 2011; Legrand
et al., 2011; Wood, 2011; Garber et al., 2012; Godman et al., 2012d;
Harper et al., 2012; Mannuci et al., 2012; Lothian Prescribing Bul-
letin, 2012;Marshall et al., 2013). The EMAreported onNovember
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Table 3 | Key issues for authorities to consider when planning patient registries post-launch.
Events/timing Key considerations regarding patient registries
Funding and
other
considerations
Funding
• Explicit and transparent funding arrangements need to be agreed before initiation
• Feasibility and potentially pertinence (depending on the nature of the registry) for joint arrangements between authorities and commer-
cial organizations, as seen with the registry for natalizumab in France (Wettermark et al., 2010a; Papeix et al., 2012) and the registries in
Italy through AIFA (Italian Reimbursement Agency; Adamski et al., 2010;Wettermark et al., 2010a; Garattini and Casadei, 2011; Jommi,
2012; Siviero et al., 2012)
• Any funding arrangements need to be transparent
Legal considerations
• Compliance with current regulations and legal requirements in each country (although there is a lack of regulations in many countries)
Ownership
• A priori agreement regarding ownership
Endorsement
• Registry endorsement by leading research groups/scientiﬁc societies, authorities, and patient groups
Timing • Timelines: ensure sufﬁcient time is made available to develop “user friendly” registries that will fully capture all the patient variables
of interest and which satisfy the interests of all key stakeholder groups as compromise will be inevitable. This includes:
◦ Ensuring as far as possible ease of use and acceptability of effort of all those involved
◦ Ensuring the competence of those entering the data at every data entry point, especially with key issues such as adverse events;
enhanced if patients are already experiencing difﬁculties with their condition such as depression, sleep disorders, fatigue and
mobility, as seen in patients with multiple sclerosis. It helps if the disease area is the specialty of those entering the data
• Data functionality of patient registries need to be considered early pre-launch (Figure 1), and time given to recruit personnel competent
in computer science and knowledgeable in the major medical issues for the disease area. This will facilitate the development of user
friendly screens and data entry to enhance the completeness and accuracy of data entry. In addition, incorporate systems that help
detect errors quickly regarding data entry, e.g., trigger tools
6, 2011 that there had already been 256 spontaneous reports of
serious bleeding resulting in deaths in the EudraVigilance database
(EMA, 2011).
Table 1 and Table A1 in the Appendix document the exten-
sive range of activities initiated across Europe. These include
educational activities pre-launch in Stockholm County Council,
Sweden, as well as post-launch activities among regions and local-
ities in Germany, Spain, Sweden, and the UK. There were also
prescribing restrictions in some countries alongside the develop-
ment of shared care protocols between ambulatory and hospital
care to improve interface management and enhance the subse-
quent quality of care (Godman et al., 2012e). It is suggested that
these activities reduced subsequent bleeding among patients in
practice, especially among those with poor renal function and, as
a result, potentially helped preserve the availability of dabigatran
across Europe. This is unlike that situation seen with a number
of drugs described earlier including zimelidine, COX-II inhibitor
drugs, cerivastatin, and rimonabant (Fagius et al., 1985; Carlson,
1999, 2000; Friedman et al., 1999; FDA, 2002; Merck, 2002, 2004;
MHRA UK, 2004; Calfee and Pinell, 2005; European Medicines
Agency [EMA], 2009; Moreira et al., 2009; O’Shaughnessy, 2009;
Eichler et al., 2011; Ioannides-Demos et al., 2011; Kappos et al.,
2011; Keegan, 2011; Dietrich and Horvath, 2012). However, it
is difﬁcult to substantiate this without deﬁnite research. Having
said this, reimbursement of dabigatran has recently been rejected
in Poland due to concerns with excessive bleeding and deaths
(Table A1 in the Appendix).
There have also been issues with the additional costs of dabi-
gatran versus warfarin at GB£919.80 (€1060) per patient (UK)
given the growing prevalence of AF with currently over 4.5–6 mil-
lion patients across Europe and rising (Lloyd-Jones et al., 2004;
Stewart et al., 2004; Camm et al., 2010; Pink et al., 2011; Mannuci
et al., 2012; Marshall et al., 2013). However, there is less of a bud-
get differential in Sweden (Davidson et al., 2013). These combined
issues led to (i) prescribing restrictions in some countries along-
side prior authorization schemes, e.g., Austria, Belgium, Finland,
NHS Bury (initially), Slovakia, and Slovenia, (ii) delays with reim-
bursement in others including Croatia (still undergoing review),
the Netherlands, Norway (only just reimbursed), and Portugal
(150 mg); as well as (iii) price:volume and other agreements (risk
sharing) to lower the price of dabigatran, e.g., Ireland, the Nether-
lands, and Slovenia as well as potentially in Croatia (Table 1 and
Table A1 in the Appendix). These concerns have also resulted in
dabigatran not being reimbursed/not preferred as an alternative
in some countries and regions including Estonia, Lithuania, Loth-
ian Health Board (Scotland), NHS Cornwall Community Health,
the Republic of Serbia, and Turkey (Table A1 in the Appendix).
Prescribing restrictions and risk sharing arrangements are no
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Table 4 | Key considerations among stakeholder groups to optimize the managed entry of new drugs (Garattini et al., 2008; Godman et al., 2008,
2009c, 2012a,b,d;Wettermark et al., 2008, 2010a,c; Coma et al., 2009;Adamski et al., 2010; Sermet et al., 2010; Gustafsson et al., 2011; Kolasa et al.,
2011;Voncˇina et al., 2011; Cheema et al., 2012; Siviero et al., 2012; Godman and Gustafsson, 2013).
Stakeholder Key considerations among stakeholder groups to optimize the managed entry of new drugs
Health authorities/
health insurance
companies/
physician
associations
Pre-launch
• Plan early for the launch of new drugs especially those that could have an appreciable budget impact and/or safety considerations.
This can be through working with countries/regions already engaged in such activities
• Work alongside key multi-professional groups including independent pharmacotherapeutic experts such as general practition-
ers, pharmacists, and clinical pharmacology groups. This will help with critically appraising the potential role and value of new
treatments ahead of their launch, as well as with developing robust budget impact models for future forecasts. Where possi-
ble, Drug and Therapeutic Committees (DTCs) and expert groups should have a major role to ensure consistent priorities for
recommendations across divergent pharmacotherapeutic groups
• Work with regulators to:
◦ Review potential areas of concern with new treatments, especially around safety issues and potential ways to address this
◦ Check information provided by commercial organizations is comprehensive, addressing any potential publication bias (Melander
et al., 2003; Kirsch et al., 2008; Martin, 2012). The need for this should reduce with ongoing activities among pharmaceutical
companies to fully disclose trial data (Kmietowicz, 2013)
• Plan early for the:
◦ Incorporation of any pharmacogenetic tests that should to be available when a new “valued” drug is launched to enhance its
appropriate use
◦ Development of any patient registries to assess the effectiveness/safety of new drugs in practice (pharmacovigilance) as well
as monitor prescribing against agreed guidance (Table 3)
◦ Any necessary re-designing of services, e.g., anticoagulation services with the launch of new anticoagulants
• Regularly assess which products will lose their patent in the coming 1–2 years to help fund new premium priced drugs in the
disease area/related disease area – especially with growing resource pressures. These activities will assist ﬁnancial planning
generally
• Work with pertinent patient groups especially regarding new treatments that could have serious patient issues to help instigate
appropriate educational campaigns for physicians and patients pre- to post-launch. Similarly also with key physicians, including
those within DTCs, to develop suitable educational and communication materials including guidelines for physicians
Peri-launch
• Consider the development of any potential new quality or prescribing indicators together with key stakeholder groups within and
across European countries. This includes their assessment in practice, acknowledging that any indicators developed must have
content validity, face validity, concurrent validity, construct validity and predictive validity
• Include any indicators developed in new guidance/guidelines and, if appropriate, within ongoing ﬁnancial incentive schemes for
physicians to optimize the use of new premium priced drugs at launch
• Be critical of any proposed risk sharing arrangements using the criteria summarized inTable 2 – mindful that such arrangements
post-launch could facilitate reimbursement and funding of new premium priced drugs (TableA1 in theAppendix – e.g., Netherlands
and Slovenia)
• Continually check likely launch dates for new treatments with pertinent pharmaceutical companies to improve ﬁnancial planning
Post-launch
• Use administrative and/or medical databases to compare “real world” patients with those included in Phase III RCTs in terms
of their clinical features, treatments, and potential outcomes to further reﬁne prescribing guidance and/or reimbursed prices
especially if greater co-morbidity in “real world” patients (Joppi et al., 2013)
• Build in regular reviews of any reimbursement/funding/guidance especially as more data becomes available, e.g., more recent
data challenging “no patient monitoring” with dabigatran especially if “no patient monitoring” was built into submitted economic
analyses
• Monitor physician adherence to any agreed guidance/reimbursement restrictions and potentially instigate academic detailing and
other activities where continued concerns with prescribing
(Continued)
www.frontiersin.org May 2013 | Volume 4 | Article 39 | 11
“fphar-04-00039” — 2013/5/13 — 13:14 — page 12 — #12
Malmström et al. Dabigatran – a case history
Table 4 | Continued
Stakeholder Key considerations among stakeholder groups to optimize the managed entry of new drugs
Physicians Peri-launch
• Work with health authorities and health insurance companies pre-launch to critically review new treatments, especially where there
are concerns with patient safety, to help enhance their appropriate use at launch and their retention on the market
• Provide guidance to health authorities and health insurance companies regarding optimal patient populations that maximize the value
of new drugs, as well as potential quality/prescribing indicators
• Provide input into discussions on the potential value of pertinent pharmacogenetic tests that may help optimize the use of new drugs
post-launch
• Help with the development of educational materials for physicians and patients peri- and post-launch including the development of
any clinical guidelines based on agreed guidance
• Assist with the design of any patient registries prior to launch, and follow this up after launch (Table 3). This can also include programs
that measure drug sequencing against any agreed guidance
• Help authorities critically assess proposed risk sharing arrangements, especially regarding the administrative burden and other key
issues (Table 2)
• Assist hospital and ambulatory care DTCs with critically evaluating new treatments, as well as with the planning of any interface
arrangements to improve the co-ordination of care between primary and secondary care physicians post launch
Post-launch
• Provide input into any patient registries (Table 3) to help assess the true value of the new drug especially where there are concerns
with safety in a wider co-morbid population post launch than those enrolled into Phase II and III trials
• Provide input when clinical guidelines are revised as more data becomes available
Patient
organizations
Pre-launch
• Provide input to health authorities and health insurance companies pre-launch regarding any safety and effectiveness issues for new
drugs from the patients’ perspectives
• This includes any pertinent pharmacogenetic tests that help optimize the use of new drugs to patient populations where the beneﬁt:risk
ratio (and hence “value”) is maximized
Pre- and peri-launch
• Provide input into the design and distribution of any patient information regarding new drugs, especially where potential safety issues,
pre- and peri-launch
• Provide input into the design of any quality/prescribing indicators for new drugs especially where there are issues of safety and
sequencing as well as where compliance is likely to be a concern
Post-launch
• Help further reﬁne information for patients as more knowledge becomes available about the new drug, especially regarding key
side-effects and their implications
• Help disseminate factual information to patients if pertinent, especially where there are exaggerated claims unduly raising expectations
among patients or where issues of side-effects have not been adequately disseminated
Commercial
organizations
Pre-launch
• Interact early with pertinent health authorities and health insurance companies, especially for new premium priced drugs, to review
key comparator and outcome data to include in Phase II/III clinical trials. Comparator and outcome data will depend on the disease
area and target prices. Included in this should be discussions regarding resource issues and budget impact at launch to aid planning,
acknowledging the particular characteristics of each market
• This may include discussions on study design with increasing knowledge of pharmacogenomics and the implications for subsequent
trial designs with potentially smaller populations (this will be explored further in future papers)
(Continued)
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Table 4 | Continued
Stakeholder Key considerations among stakeholder groups to optimize the managed entry of new drugs
• Provide health authorities and health insurance companies with all relevant data in a timely fashion pre-launch, rather than selective
data, to aid decision making and reduce scepticism.This is important to address current concerns that manufacturers are still hiding/not
providing data that potentially reduces the value of their product (Martin, 2012); although some companies are now addressing this
(Kmietowicz, 2013)
• Relevant data includes key adverse event data or pharmacokinetic data - especially if there are concerns about potential claims in
practice as seen with concerns with the “no requirement for patient monitoring” with dabigatran
• Be pragmatic when planning target prices taking into account key decision making criteria for the pertinent country or region, including
either cost/QALY considerations or clinical data requirements for new drugs to be seen as innovative or adding clinical value. This
includes any discounts or rebates as part of any risk sharing arrangements (Table 2), acknowledging that the majority of new drugs
are seen as similar by payers, with only a minority seen after critical evaluation to have added patient beneﬁts compared with
existing standards.These considerations have grown in importance with ongoing resource pressures, i.e., mindful of opportunity cost
considerations within health authorities and health insurance companies
Peri- and post-launch
• Resist the urge to over promote new drugs especially to the public where there are safety issues, thereby reducing the potential for
further restrictions/early withdrawal
• Potentially monitor and reﬁne risk sharing arrangements as more data becomes available
doubt preferred by manufacturers versus not having their drugs
reimbursed.
The weighing up of the beneﬁts and concerns with dabiga-
tran make it increasingly important for European countries and
regions to develop and reﬁne models to further improve the man-
aged entry of new premium priced drugs, even if they do not have
a tradition of Health Technology Assessment (HTA). The alterna-
tive could be reduced resources to fund new drugs in the future,
especially with a growing elderly population, which is already hap-
pening (Garuoliene et al., 2011a,b; Godman et al., 2011c, 2012b;
Taylor, 2011). As mentioned previously, budgetary pressures are
growing as a result of the number of new biological drugs in
development (EvaluatePharma, 2012; Godman, 2013) including
new cancer drugs (Nagle et al., 2008; National Cancer Institute,
2010; Sullivan et al., 2011; Mullard, 2012), which are now costing
up to US$10,000–25,000 (€7580–18,960) per patient per month
(Selyukh, 2011; Yukhananov, 2011; Kaiser, 2012; UK Medicines
Information, 2012; UKMi Medicines Information, 2013). Such
models may also reduce the possibility of new drugs such as dabi-
gatran being withdrawn from the market due to a greater level of
side-effects in a wider co-morbid population than that included
in the clinical trials (Joppi et al., 2013). None of these alterna-
tive scenarios are in the best interests of any key stakeholder
group.
Moreover, it is critical that health authorities and health insur-
ance companies take full advantage of the increasing availability
of standard drugs as generics to help fund increased volumes
and new premium priced drugs in the future (Frank, 2007; Jack,
2008; Godman et al., 2012a,b,f). For example, expenditure on pro-
ton pump inhibitors (PPIs) and statins would have been GB£449
million (€520 million) higher in Scotland in 2010 without appre-
ciable demand-side measures enhancing the prescribing of low
cost generics for its 5.2 million population (Bennie et al., 2012;
Godman et al., 2012b). This activity is driven by global sales of
products likely to lose their patents between 2008 and 2013 esti-
mated at US$50–100bn (€38–76bn), and considerably higher for
subsequent years (Frank, 2007; Jack, 2008; Godman et al., 2012b,f),
out of global sales of pharmaceuticals estimated at US$820bn
(€625bn) in 2009 (EATG, 2009).
The next stage of our research will be to assess the inﬂu-
ence of the plethora of health authority and health insurance
company activities (Table 1 and Table A1 in the Appendix) on
subsequent utilization of dabigatran and other NOACs, along-
side ongoing reforms, to further reﬁne the suggested model
(Figure 1). This should also help with future recommen-
dations regarding potential demand-side measures that could
be introduced to further improve the managed entry of new
drugs, based around the four Es (Wettermark et al., 2009a).
This includes the implications for all key stakeholder groups
(Table 4). We are already seeing health authorities and health
insurance companies monitor the effectiveness and safety of
patients prescribed dabigatran and other NOACs, and this
will grow.
In the meantime, we hope we have demonstrated why it is
imperative that health authorities and health insurance com-
panies continue to develop and reﬁne new models to better
manage the entry of new drugs in the future. In addition, we
hope we have provided direction to all key stakeholder groups
based on our considerable experience to further stimulate this
debate in this critically important area. This especially as the
constant introduction of new premium priced drugs is seen as
the greatest challenge to the continued provision of equitable
and comprehensive healthcare in Europe (Garattini et al., 2008;
Godman et al., 2012d).
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CONCLUSION
There have been multiple activities pre- to post-launch
among authorities across Europe to improve the prescrib-
ing of dabigatran, especially in elderly patients where there
are concerns with their renal function. In addition, address
potential concerns with the budget impact of dabigatran
through for instance price:volume agreements and prescribing
restrictions.
We believe and recommend, based on the experiences with
dabigatran and other new premium priced drugs, that it is essen-
tial for authorities to develop new models to better manage the
entry of new drugs in the future (Figure 1). This is becom-
ing critical given the number of new premium priced drugs in
development.
Critical activities for health authorities and health insur-
ance agencies pre-launch in the future involve horizon scan-
ning and budget planning activities. This includes identify-
ing products likely to lose their patent within the next 1–2
years. In addition, educational materials and clinical guidance
need to be developed pre-launch with the help of physicians
and patient groups. Key peri-launch activities include devel-
oping prescribing indicators for new treatments as well as
the critical appraisal of any proposed risk sharing arrange-
ments, assessed against the criteria documented in Table 2.
Essential post-launch activities include monitoring of prescrib-
ing against agreed guidance. Increasingly also entering patients
into registries to monitor the effectiveness and safety of new
drugs in wider patient populations having considered key issues
(Table 3).
Without suchmodels, authoritiesmaywell struggle tomaintain
the European ideals of equitable and comprehensive healthcare as
well as ensuring funding for new “valued” treatments in target
populations. Consequently, the development of new models to
better manage the entry of new drugs should be in the interest of
all key stakeholder groups.
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APPENDIX
TableA1 | Examples of health authority and health insurance company activities regarding dabigatran for the prevention of stroke in adults with
non-valvular AF among European countries to the beginning of 2013 (building on EU marketing authorisation – (Boehringer Ingelheim, 2011a;
Marshall et al., 2013).
Country Date dabigatran
reimbursed for AF
Summary of activities
Austria (Godman
et al., 2008, 2009a;
Wettermark et al.,
2009a; Voncˇina
et al., 2011;
Therapie Tipps,
2012)
February 2012 Post-launch
Enforcement – Ex ex-ante approval by the head physician of the patient’s social health insurance fund
before reimbursement of dabigatran; otherwise 100% co-payment (mirroring other situations). This is now
fully automated, with the ﬁrst prescription typically taking approximately 30 min to approve
The renal function has to be assessed and recorded prior to initiation of therapy with dabigatran through
determining Creatinine-Clearance (CrCl) levels to exclude patients with severe renal dysfunction (= CrCl <
30ml/min). In addition during treatment, renal function has to be monitored where a decline is envisaged,
e.g., patients with hypovolaemia, dehydration and the use of speciﬁc additional medication, and renal
function has to be assessed at least once a year in patients aged 75 or older, and/or in patients with
compromised renal function. Otherwise 100% co-payment
Health Insurers (WGKK – Vienna) have also stated that patients who are well adjusted on Vitamin K
antagonists should not be switched to dabigatran as there is no additional clinical beneﬁt, enhanced by
currently no known antidote.
Belgium
(Federal Agency for
Medicines and
Health Products
(FAMHP), 2011)
August 2012 (i) Reimbursement
• 2 × 150 mg per day based on the SPC and the patient is not subject to one of the following:
◦ Older than 80 years;
◦ Treated with verapamil;
◦ Serious renal insufﬁciency
• 2 × 110 mg dose – reimbursed in the absence of serious renal insufﬁciency but without age or
verapamil restrictions
(ii) Education (pre-launch)
• 25th November 2011, the Federal Agency for Medicines and Health Products issued an update
concerning the risk of fatal bleeding with dabigatran. This was based on the CHMP’s
recommendations at the EMA that precautionary measures need to be strengthened in the case of
renal insufﬁciency. Physicians were also informed of the CHMP recommendations in a letter
• In March 2012, the Belgian Centre for Pharmacotherapeutic Information stated that:
◦ Based on the currently available studies, dabigatran and rivaroxaban appear to be as efﬁcacious as
warfarin in the prevention of thrombo-embolism in non-valvular atrial ﬁbrillation
◦ Their risk-beneﬁt ratio did not seem to be superior to VKAs when VKAs were used in appropriate
doses within the INR range
◦ Awaiting additional studies, and taking into account the limited data and high price of NOACs, VKAs
remain the ﬁrst choice for many patients
◦ Dabigatran and rivaroxaban can be alternatives in patients for whom treatment with a VKA is
difﬁcult to control
◦ In the absence of comparative studies between dabigatran and rivaroxaban, there are no arguments
to prefer one product to the other
◦ NOACs can lead to speciﬁc medicine interactions (but to a lesser extent than with VKAs) and to
over-dosing when renal function declines (need to pay attention in the elderly).
(Continued)
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Table A1 | Continued
Country Date dabigatran
reimbursed for AF
Summary of activities
Peri-launch (Enforcement)
• Dabigatran was reimbursed as a chapter IV medicine in AF patients. A chapter IV medicine can only be
prescribed subject to prior approval from the advising physician of the patient’s health insurance fund -
otherwise a 100% patient co-payment applies
• Reimbursement is restricted to one pack of 60 × 150 mg and three packs of 180 × 150 mg, with a
maximum validity period of 300 days
• Reimbursement can subsequently be extended for renewable periods of 360 days for four packs of
180 × 150 mg per period
• Concomitant reimbursement of dabigatran with another oral anticoagulant is not allowed
Post-launch (Education, Engineering)
• As part of the risk management plan for dabigatran, a warning card/patient card was made available for
patients to keep with them at all times
• By giving this card to patients, it is envisaged that physicians and pharmacists will enhance the
appropriate use of dabigatran and limit potential side effects - especially as the patient is encouraged to
show this card to every physician, pharmacist or other health professional
Croatia Under evaluation Reimbursed for the prevention of venous thromboembolism in patients undergoing hip or knee surgery,
and only in hospitals, with prescriptions traced in hospitals if abuse is suspected.
Under consideration for the prevention of stroke and systemic embolism in adult non-valvular AF patients
including price:volume agreements and/ or co-payments. There are also ongoing discussions regarding
safety issues
England (Horsley,
2010; Elton et al.,
2011; Keele
University School
of Pharmacy, 2012;
Midlands
Therapeutic Review
and Advisory
Committee
[MTRAC], 2012;
National Institute
for Health and
Clinical Excellence,
2012; Marshall
et al., 2013; NHS
Improvement.
Guidance on Risk
Assessment and
Stroke Prevention
for Atrial Fibrillation
(GRASP – AF),
2013)
August 2011 Post-launch
(A) National – NICE:
Dabigatran is recommended in line with the licenced indication, with the decision whether to start
treatment made after an informed discussion between clinicians and patients about the risks and beneﬁts
of dabigatran versus warfarin.
For patients already on warfarin, the potential risks and beneﬁts of switching to dabigatran should be
considered in light of current INR control.
(B) Regions (Midlands – MTRAC) – Education
Guidance stating that warfarin remains the ﬁrst-line option for anticoagulation in patients with AF at high
risk of a stroke, and PCTs should ensure optimal existing warfarin therapy services – including access to
INR clinics, use of computerised decision-support software, and access to drugs for patients who are
allergic to warfarin (the latter is rare in practice)
In view of the considerable ﬁnancial implications, dabigatran treatment should only be prescribed for those
patients:
• with co-morbidities who are adherent to warfarin monitoring and lifestyle requirements but need
frequent co-prescribed medications that interact with warfarin and affect the patients’ time in the
therapeutic range (TTR)
• who are adherent to monitoring and lifestyle requirements but whoseTTR remains unacceptable
despite attempts to optimise treatment with warfarin (TTR rates should be set locally)
Alongside this, patient follow-up via agreed shared care protocols with ongoing monitoring of prescribing
costs and feedback from Pharmaceutical Advisers.
(Continued)
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Table A1 | Continued
Country Date dabigatran
reimbursed for AF
Summary of activities
Coventry and
Warwickshire Area
Prescribing
Committee (2012);
Interface – A
monthly medicines
and prescribing
bulletin for
healthcare
professionals in
East Lancashire
focusing on new
therapies (2011);
East Lancashire
NHS Medicines
Management
Health Economy
New Medicines
andTreatments
Group - Dabigatran
for prevention of
stroke in
non-valvular atrial
ﬁbrillation (2012);
NHS Cumbria, NHS
Lancashire
(2012a,b);
(C) Localities
(i) Coventry and Warwickshire Area Prescribing Committee (Education, engineering):
• Dabigatran should only be initiated by a specialist
• Follow on prescribers should receive a checklist from the initiating specialist indicating patients are
suitable for dabigatran and have received appropriate guidance from the specialist
• No follow-on prescribing if checklist is unavailable from the specialist
(ii) East Lancashire (Education):
Initially not approved (October 2011); but subsequently approved for usage in January 2012. As part of this:
• Patients currently stable on warfarin therapy should not be considered for dabigatran.
• Dabigatran should only be considered for prescribing by appropriate specialists (including GPs
initiating therapy as part of specially commissioned anti-coagulation services)
• Dabigatran should only be considered as an alternative to warfarin for stroke prevention in AF patients
in the following:
1. Patients for whom warfarin is contraindicated or not tolerated or not suitable (e.g., Mental/cognitive
impairment) – NOTE: If warfarin is contra-indicated due to increased bleeding risk then dabigatran
would also be contra-indicated.
2. Patients who are poorly controlled on warfarin, i.e. a clinical judgement based on patient reviews
relating to the extent INR results are outside of the target therapeutic range (TTR). If dabigatran is
considered as a suitable alternative, prescribers must fully document the rationale
(iii) NHS Bury
• Greater Manchester Medicines Group [GMMMG] and the Greater Manchester and Cheshire Cardiac
and Stroke Network [GMCCSN] agreed joint guidance for the use of dabigatran behind warfarin. This
resulted in NHS Bury establishing a “Gateway” whereby GPs had to seek permission from NHS Bury
to prescribe dabigatran
• This resulted in very few requests, with even fewer requests granted due to ongoing clinical and
economic concerns.
• Following NICE advice [TA249], NHS Bury have instigated a number of educational activities with
Consultants and GPs including joint symposia and the production of local prescribing guidance
• In addition, encouraging GP practices to work with the NHS Improvement Tool – GRASP – AF
(Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation) to identify patients with AF
at high risk of a stroke that are currently not properly anti-coagulated as potential candidates for
NOACs
(iv) NHS Cornwall Health Community (Education)
• Prescribing of new NOACs discussed at the Area Prescribing Committee
• Development of prescribing guidance stating that warfarin remains ﬁrst line option but noting that
dabigatran can be considered for patients with AF not taking warfarin for reasons of intolerance,
previous signiﬁcant adverse effects with warfarin, interactions, circumstances where routine
monitoring may be impractical, and those with AF with poor INR control on warfarin
• Prescribing of dabigatran (and other new NOACs) monitored monthly and reported back to GPs during
forum meetings between prescribing advisers and GPs
(Continued)
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Table A1 | Continued
Country Date dabigatran
reimbursed for AF
Summary of activities
(v) NHS Lancashire/ NHS Cumbria (Education, economics):
• Developed a consensus statement for NOACs together with NHS Cardiac and Stroke Networks in
Lancashire and Cumbria. This included:
◦ On the balance of risks and beneﬁts suggest warfarin is considered for high risk atrial ﬁbrillation
patients i.e., those with CHADS2 > 2. Where CHADS2 < 2, risk assess using CHA2DS2VASc and
reconsider the need for anticoagulation.
◦ NOACs are recommended as an option where warfarin is either contraindicated or where the
patient has a documented hypersensitivity to or intolerance of coumarin anticoagulants severe
enough to cause treatment withdrawal. In situations where repeated INR testing/monitoring may
be impractical, the use of a NOAC should be considered. However, increased bleeding risk as a
contraindication to warfarin also applies to NOACs.
◦ An assessment of bleeding risk should be considered before starting anticoagulation. The
HAS-BLED score is recommended to assess bleeding risk in AF patients, however, remember
stroke and bleeding share risk factors.
◦ For patients who are already taking warfarin, the potential risks and beneﬁts of switching to a NOAC
should be considered in light of their level of INR control. Where patients are spending over 65% of
their time in the therapeutic range (TTR) on warfarin, there is likely to be little beneﬁt in switching to
a NOAC.
◦ For new patients requiring anticoagulation, warfarin should be considered and, after an informed
discussion with the patient, should be initiated with its effectiveness assessed after 3 months of
treatment.
◦ The decision about whether to start a NOAC should be made after an informed discussion between
the clinician and the patient about the risks and beneﬁts of NOACs compared to warfarin. Patient
Decision Aids are being developed by the Medicines and Prescribing Centre (NPC of NICE) and
their use is endorsed by this consensus group.
◦ Whilst NOACs have a shorter half-life than warfarin, they have no simple antidote. Whilst they don’t
need anticoagulation monitoring, there is no standardised easy way of measuring their
effectiveness. Conversely, warfarin has been in use for over 60 years, its effects are measurable
and can be rapidly reversed in the event of major bleeding
• NHS Lancashire and NHS Cumbria also produced guidance for the prescribing of dabigatran. This
included:
◦ Contraindications
◦ Advice on how to convert patients from warfarin to dabigatran and conversion from dabigatran to
warfarin
◦ Interactions with other medicines
◦ Advice on the discontinuation of dabigatran based on renal function
• Potential rebate schemes were initially discussed to reduce the costs of dabigatran to NHS
Lancashire. However, this was not taken forward with the change to a Clinical Commissioning Group
Estonia Not reimbursed Dabigatran rejected for this indication as not seen as sufﬁciently cost-effective versus warfarin in view of
its high acquisition costs
(Continued)
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Table A1 | Continued
Country Date dabigatran
reimbursed for AF
Summary of activities
Finland
(Martikainen et al.,
2010; Godman
et al., 2011a)
April 2012 Post-launch (enforcement)
Reimbursement restrictions (Enforcement) – limiting the reimbursement of dabigatran to patients with risk
factors where satisfactory control has not been reached with warfarin; alternatively, warfarin cannot be
prescribed due to side-effects or contra-indications.
Enforcement at the pharmacy with on average 16 days needed for requests to be centrally reviewed and
authorised. 100% co-pay without authorisation.
France (Sermet
et al., 2010;
Godman et al.,
2012a; Haute
Authorite de Sante
– Commission de la
Transparence, 2012)
ASMR Rating
February 2012
Peri-launch
Dabigatran classiﬁed as ASMR V (no additional therapeutic value) compared with current therapies for the
prevention of strokes in adults at risk who have “non-valvular atrial ﬁbrillation” and are considered to be at
risk of stroke.
Post-launch
(a) April 2012 – Education:
(i) Publication of information about dabigatran from the authorities including a warning from the medicine
agency ANSM (ex afssaps):
• risk of haemorragia and overdose
• absence of biological tests and an antidote
(ii) Publication of advice for (1) change of prescribing from or to other anticoagulants, (2) patients
undergoing surgery
(b) May 2102
Translation of the latest advice from the EMA
Once reimbursed, patients will be followed up to assess the effectiveness and safety of dabigatran in
practice (pharmacovigilance)
Germany (IQWiG,
2010;
Kreatinin-Clearance
Rechner (Creatinine
Clearance
calculator), 2013)
August 2011 Peri- and post-launch
Activities (education and engineering) included the following:
• Information from State and National Physician Associations to ambulatory care physicians stressing
concerns and potential sanctions with “off label” use in AF prior to its licensing approval
• Physician Associations stressing when launched that the current knowledge regarding safety with
dabigatran was insufﬁcient to answer all questions, and physicians should be careful with prescribing
particularly in the elderly
• The reporting of deaths from excessive bleeding further endorsed these concerns. As a result, limited
prescribing in practice in ambulatory care
• A warning letter from Boehringer Ingelheim following issues and deaths from excessive bleeding in
Japan. In the letter, BI stated that patients should not be prescribed dabigatran if their creatinine
clearance is <30 ml/min and/ or signiﬁcant renal impairment. In addition, the need to monitor renal
function when using dabigatran especially in patients prone to poor renal function or where renal
function is deteriorating (measured using the Cockroft-Gault formula)
• Information to patients about anti-coagulation in general including dabigatran
(Continued)
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Table A1 | Continued
Country Date dabigatran
reimbursed for AF
Summary of activities
Ireland (National
Centre for Pharma-
coeconomics, 2011;
Burke, 2012; Health
Service Executive
(HSE) Ireland.
Primary Care
Reimbursement
Service (PCRS)
Online Services,
2012)
July 2012 Peri- and post-launch
August 2011: The National Centre for Pharmacoeconomics (NCPE) stated that “dabigatran etexilate could
be considered a cost effective treatment for the prevention of stroke and systemic embolism for adult
patients with atrial ﬁbrillation and one or more of the speciﬁed risk factors. However there are uncertainties
associated with some of the clinical input data and the model assumptions in addition to the considerable
opportunity cost, in the region of €13 million over 10 years.” In view of this a reduction in price is
recommended to ensure value for money for the health service in Ireland (HSE).
November 2011: A HSE Statement advises that the drug will not be reimbursed if prescribed for any new
patients for SPAF (Stroke prevention in patients with AF).
July 2012: A HSE Statement states that:
Warfarin is the recommended ﬁrst line agent for stroke prevention in atrial ﬁbrillation. Dabigatran should be
reserved for:
• Existing patients on warfarin with poor INR control despite adhering to monitoring and lifestyle
requirements. Documentation of attempts to optimise warfarin therapy is required.
• Existing patients who require regular periodic treatment with medicines that are known to interact
with warfarin
• Patients with a documented allergy to warfarin
As part of the implementation, the physician responsible has to make a speciﬁc application for each patient
to HSE. Otherwise, pharmacists will not be reimbursed for dispensing dabigatran to patients for SPAF
without prior reimbursement approval (enforcement)
October 2012: Following the NCPE pharmacoeconomic assessment (August 2011), the manufacturer
reduced the price of dabigatran. At this revised price, the NCPE now considers dabigatran to be cost
effective in this situation
Italy (Adamski et al.,
2010; Cheema
et al., 2012; Jommi,
2012; Siviero et al.,
2012)
Undergoing
evaluation
Pre-launch
• Educational meetings at regional and national level with different stakeholders to (i) identify possible
prescriber(s) (cardiologists only or GPs as well) and the target population; (ii) deﬁne a sustainable price
and (iii) deﬁne the features of a follow-up programme for patients treated with dabigatran
• Forecasting the potential budget impact in the ﬁrst and second year post-launch with the help of key
stakeholder groups
Post-launch
• Planning a national registry containing details of the clinical characteristics, current pharmacological
treatments, and potentially outcomes of patients with AF prescribed dabigatran
• To limit the prescribing to specialists only (cardiologists, others) and to involve the GPs in the follow-up
of treated patients;
• To network prescribers (specialists) and GPs as well as instigate educational activities among specialists
(prescribers) and GPs according to their needs
Lithuania Not reimbursed Reimbursement was rejected at the end of 2012 as dabigatran was not seen as sufﬁciently cost-effective
versus warfarin
(Continued)
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Summary of activities
Netherlands
(Medicine Balance
[MEDICIJNBAL-
ANS],
2012)
December 2012 Peri- to post-launch(education, economics)
• The National Health Council advised the Ministry of Health to reimburse dabigatran (and rivaroxaban) but
additional research concerning the speciﬁc Dutch situation was needed. The research should be
performed in the real world population seen in clinical in practice
• The Ministry of Health subsequently asked prescriber organizations to establish a guideline for the safe
and responsible introduction of dabigatran. The guideline to contain a protocol for calamities, prioritized
patient groups (which groups are high priority) and instructions to contribute to a patient registry
• The national guideline has now been produced. Each hospital is expected to produce its own protocol
based on the national guidance as well as make arrangements with GPs and ambulance services
• As part of reimbursement, the Ministry of Health sought a price-volume agreement with the
manufacturer
• In addition, a review has been made available by the Institute for the Rational Use of Medicines giving
an overview of the current evidence surrounding dabigatran in AF for physicians. Experts are being used
to initiate online discussions on the new website from this institution to further enhance appropriate
prescribing (Education)
Norway January 2013 Peri-launch
• Dabigatran was recently assessed by the National Medicines Agency of Norway (NOMA) and
considered to be cost-effective for the prevention of stroke in adults with non-valvular AF
• The Ministry (as of October 2012) favoured the reimbursement of dabigatran from 1 January 2013, and
the Budget Bill was voted in on 5 December 2012
• No ongoing activities such as price: volume agreements or educational activities
Poland (Agencja
OcenyTechnologii
Medycznych Rada
Przejrzystos´ci,
2012)
Not reimbursed TheTransparency Council of the Polish HTA Agency assessed dabigatran for its potential inclusion in the
national reimbursement list
TheTransparency Council subsequently rejected reimbursement due principally to safety concerns. The
Council was concerned about the number of serious bleeds and deaths that had already occurred in the
United States and New Zealand soon after its launch in these countries.
Portugal August 2011 for
110 mg (when PL
granted)
• Reimbursed for 110 mg for the prevention of stroke in patients with atrial ﬁbrillation once approved by
EMA, as already reimbursed for prophylaxis in patients undergoing hip and knee surgery (current
legislation in Portugal). As a result, appreciably increasing utilisation of 110 mg strength
• 150 mg is currently not reimbursed for AF, but is undergoing evaluation alongside an accompanying
pharmacoeconomic study versus warfarin which was submitted by the manufacturer to demonstrate
the cost-effectiveness of 150 mg dabigatran versus warfarin
• Ongoing activities to lower the reimbursed acquisition cost (price) for AF patients for the 110 mg
strength
The Republic of
Serbia
Not reimbursed Dabigatran is currently not reimbursed in Serbia principally due to concerns with its price/ budget impact
versus warfarin for the prevention of stroke in patients with AF and the perceived limited beneﬁts in
practice.
Republic of Srpska Not currently
reimbursed
• The manufacturers made a submission to the Health Insurance Fund (HIF)
• The submission has been reviewed by the HIF and proposed for inclusion in the reimbursement list
• However to date, there has been no decision to include dabigatran in the reimbursed list of drugs
(Continued)
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Scotland (NHS
Tayside, 2011; Fife
Area Drug and
Therapeutics
Committee (2012);
Health
Improvement
Scotland (2012);
NHS Highland - The
Pink One (2012);
Scottish Medicines
Consortium, 2011;
Oral anticoagulants,
2012; Marshall
et al., 2013)
August 2011 Peri-launch
National (SMC) – Dabigatran is accepted for use in accordance with the approved indication as it was seen
to be at least as effective as standard oral anticoagulation at preventing stroke or systemic embolism and
was not associated with an increased risk of major bleeding.
Post-launch (among the Health Boards) (educational)
(a) Fife (December 2011)
Dabigatran should only be prescribed in line with advice from Healthcare Improvement Scotland, i.e., on
balance of risks and beneﬁts of dabigatran, warfarin remains the anticoagulant of clinical choice for
moderate or high risk atrial ﬁbrillation patients (CHA2DS2-VASc = 2) with good INR control, and clinicians
should only consider prescribing dabigatran in patients with:
• poor INR control despite evidence that they are complying, or
• allergy to or intolerable side effects from coumarin anticoagulants
(b) Highlands (December 2011)
• Warfarin remains the anticoagulant of choice as a greater rate of GI bleeding and GI symptoms with
dabigatran
• In addition, much easier to manage major bleeding in patients with warfarin as no licensed product
available to reverse bleeding with dabigatran (unlike warfarin)
• If needed, dabigatran should only be started when patient’s INR has dropped below 2
(c) Tayside (December 2011)
• Prescribing should be restricted to patients with poor INR control on warfarin, or with allergy to or
intolerable side-effects from coumarin anticoagulants
• Under the guidance, anticoagulant clinics in NHSTayside will identify eligible patients and make
contact with relevant GPs with the decision to transfer patients resting with GPs
• In addition, prescribers should note recent MHRA advice that renal function should be assessed in all
patients before starting dabigatran. While on treatment, renal function should be assessed at least
once a year in patients >75 years and when a decline in renal function is suspected
(d) Lothian (May 2012 Bulletin)
• Dabigatran classiﬁed as “not preferred as suitable alternatives exist.”
• The main concerns were safety and the management of any bleeding episodes when they occur
Slovakia April 2012 Peri-launch
• Dabigatran was assessed by the Categorisation Committee at the Slovak Ministry of Health and
considered cost-effective for the prevention of stroke in adults with non-valvular AF. The incremental
cost-effectiveness ratio (ICER) of dabigatran versus standard treatment was estimated at €17,437, which
is below the Slovakian acceptable threshold (€18,000 per QALY gained). The sensitivity analysis
consistently demonstrated the cost-effectiveness of dabigatran.
• Only reimbursed if prescribed by cardiologists, neurologists or internists in line with the approved
indications (enforcement). One of the following requirements are also needed for reimbursement in all
indications apart from a previous stroke, TIA or systemic embolism:
◦ Chronic warfarin treatment is not properly controlled in the therapeutic range INR 2-3, and 2 out of
6 INR values are out of this range, or
◦ During the ﬁrst 3 months of warfarin treatment, INR 2–3 is not reached, or warfarin is
contraindicated
Post-launch
• Demand-side activities included local, regional and national events to discuss the reimbursed indications
and the care needed to prescribe dabigatran (education)
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Slovenia August 2012 Peri-launch
Reimbursement in line with the licensed indication in conjunction with a complex price: volume agreement
Post-launch
Demand-side activities included:
• Education of all involved specialists and primary care physicians on key safety aspects/ adverse events
with dabigatran
• Prescribing restrictions (Enforcement)
◦ Only reimbursed if initiated by an internist or neurologist in line with approved indications. This also
includes patients already on warfarin who have unstable anticoagulation, i.e., TTR < 65
◦ Patients have to be followed in a tertiary or secondary care anticoagulation centre. Patients can be
treated in primary care but only if authorized by the tertiary or secondary care centre.
◦ Every patient has to be registered in a database and followed by the IT anticoagulation programme
◦ Anticoagulation centres have to report once yearly to the tertiary centre regarding the number of
patients experiencing minor and major bleeding, thromboembolic events, as well as any deaths from
bleeding or thromboembolism
Spain (Coma et al.,
2009; Ostazen,
2011)
November 2011 (A) Post-launch activities (Basque Country)
(a) Assessment
• General evaluation of dabigatran in the prevention of thromboembolism in patients with AF performed
by the Drug Assessment and Vigilance Unit CEVIME of the Drug Directorate of the Ministry of Health
of the Basque Country. This included a budget impact analysis under three scenarios. The budget
impact for 2012 was estimated as 1.5% (7M€) of the total expenditure of primary care health
prescriptions in the most restricted scenario.
• A consensus statement (education) coordinated by the Ministry of Health, in collaboration with the
Professional Societies of Family Physicians, Hospital and Primary Care Pharmacologists, Haematology
and Haemotherapy, Cardiology, Internal Medicine and Neurology, resulted in the following restrictions
for dabigatran:
◦ Existing patients previously treated with vitamin K antagonists (VKA) where there is
hypersensitivity to acenocoumarol, warfarin or other coumarin, when INR levels cannot be properly
monitored, with abnormal INR levels or when the INR is in the correct range but thromboembolic or
haemorrhagic episodes are common
◦ New Patients: In patients with a history of ischemic stroke or high risk of intracranial haemorrhage –
otherwise second line after VKAs
• A post-marketing authorisation analysis is being performed by the Ministry of Health of the Basque
Country to assess the actual budget impact of dabigatran
• Distribution of the consensus document (education) among all healthcare professionals (primary and
specialized care) and inclusion in the common electronic medical record educational tools (all the
professionals have access to this medical record in primary and specialised care)
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(b) Engineering/ enforcement
• Routine scrutiny of the prescribing dabigatran to ensure its rational use in the Basque Health System,
according to the provisions of the Spanish Royal Decree 618/2007 of May 11th. Reimbursement/
funding is controlled by the Medical Inspection of the Ministry of Health of the Basque Country, with
funding only granted for the prevention of stroke and systemic embolism in adult patients with
non-valvular atrial ﬁbrillation with one or more of the following risk factors: (a) Stroke, transient
ischemic attack, or prior systemic embolism (ES); (b) Left ventricular ejection fraction <40%; (c)
Symptomatic heart failure Class 2 or greater under the scale NewYork Heart Association (NYHA); (d)
Age greater than or equal to 75 years; (e) Age greater than or equal to 65 associated with one of the
following: diabetes mellitus, coronary heart disease or hypertension. In addition, meeting the above
consensus criteria. This has helped to conserve its use in practice
• The Ministry of Health of the Basque Country has included in its contracts with providers (primary and
secondary care) quality of care indicators. This includes new drugs where there are concerns with
their value versus existing gold standards, which now includes dabigatran. The list is updated annually
and managed by the Basque Provinces directorates.
• Prescriptions are electronically controlled by the Drug Directorate of the Ministry of Health of the
Basque Country, and their standardized variability analysed.
(c) Post-launch activities also included (education, engineering)
• A centralized post-marketing authorisation follow-up of all patients receiving dabigatran
• Data on patients prescribed dabigatran for AF are regularly being sent from pharmacists and clinical
pharmacologists to the Ministry of Health Directorates. This electronic tool allows primary health care
physicians to self-audit their prescribing and the region to monitor dabigatran use
(B) Post-launch activities (Catalonia)
(a) Education
• General evaluation of dabigatran in the prevention of thromboembolism in patients with AF performed
by the Catalan HTA.
• A second evaluation undertaken by the DTC of the Catalan Institute of Health (CIH) resulted in a more
restricted patient population, i.e., only in atrial ﬁbrillation patients with (i) prior acenocumarol
treatment and lack of control of INR values (2–3) in more than 60% of the last assessments, in spite
of good adherence to treatment, (ii) patients who have difﬁculties to follow INR control and (iii) those
with an allergy to acenocumarol
• A third evaluation is currently being undertaken by the Catalan HTA to evaluate the different drugs
available and their potential use for the prevention of thromboembolism
• Distribution of a document describing the DTC decision to all Primary Health Care (PHC) physicians,
as well as electronic notices and warnings regularly published on physician computers (100% of PHC
physicians use computers). The same documents also distributed to hospital DTCs as well as
Cardiology, Neurology, Internal Medicine and Haematology clinics.
(b) Engineering
• Catalan Health Service contracts with providers (primary and secondary care) to incorporate quality of
care indicators including new drugs where there are concerns with their value versus existing gold
standards. This now includes dabigatran, with the list updated annually
(Continued)
www.frontiersin.org May 2013 | Volume 4 | Article 39 | 29
“fphar-04-00039” — 2013/5/13 — 13:14 — page 30 — #30
Malmström et al. Dabigatran – a case history
Table A1 | Continued
Country Date dabigatran
reimbursed for AF
Summary of activities
(c) Economics
• There are ﬁnancial incentives for Catalan Health Service providers aimed at limiting the prescribing of
new premium priced drugs with limited health gain versus current standards, with pertinent indicators
included in the current range of quality of care indicators
• Physicians who do not attain agreed standards do not receive the ﬁnancial incentive
Post-launch activities (education, engineering) also included:
• A centralized follow-up of all patients prescribed dabigatran has been established in the CIH. Patients’
age, previous treatment with oral anticoagulants or antiplatelet agents, renal function and previous
history of ischemic heart are monitored
• Patients at risk of bleeding because of abnormal or unknown renal function, or with inadequate
dabigatran prescriptions, are identiﬁed. Physicians in charge of these patients are contacted to conﬁrm
whether the indication for dabigatran conforms to CIH guidance and whether patients could be changed
to acenocumarol
• Data on patients using dabigatran for AF are regularly sent to PHC pharmacists and clinical
pharmacologists, hospitals and CIH DTCs. This electronic tool allows primary health care physicians to
self-audit, and the region to monitor dabigatran use
• A qualitative prescription study is also currently being performed among PHCs in Barcelona. All patients
prescribed dabigatran during the last semester of 2011 (n = 331) will be followed for12 months. The
objective is to evaluate dabigatran’s effectiveness and adverse effects in practice.
Sweden (Godman
et al., 2009c, 2012d;
Holmström et al.,
2009; Janusinfo,
2009; Stockholms
läns landsting,
2011; Janusinfo,
2012a; Medicin &
Läkemedel, 2012;
Östergötland, 2012;
Davidson et al.,
2013), SBU
(Swedish Council
on Health
Technology
Assessment, 2011)
November 2011 (I) National – peri-launch
• SBU alert advisory report containing a statement that dabigatran seems to be no better than warfarin
when applied to Swedish health care system
• TLV did not introduce any prescribing restrictions when authorising reimbursement for dabigatran
• Follow-up of patients in registries
(II) Regional/ County activities
(i) Östergötland County Council
Pre-launch activities (educational, economics)
• Update of the previous report on the prevalence of atrial ﬁbrillation In Östergötland
• Establishing a working party with broad representation from the departments of cardiology and internal
medicine, primary health care, representatives from the warfarin polyclinics, epidemiologist and health
economists associated with the Drug andTherapeutics Committee (DTC)
• Scientiﬁc publication of the cost-effectiveness model for dabigatran for the prevention of stroke based
on Östergötland by the Centre for Medical Technology Assessment, Linköping University, in
collaboration with Östergötland County Council
• Consensus action plan agreed 12 months before dabigatran was registered for the prevention of stroke
in patients with AF
• Recommendation from the DTC to classify dabigatran as a “focus-drug,” i.e., the prescribing unit will be
responsible for the cost of the drug. If however patients are entered into the County Council’s quality
assessment program, the cost will be borne by the County Council
• Decision by the County Council to follow the recommendation of the DTC
• Resources for treating patients allocated in the 2011–2012 drug budget
• Communication plan implemented
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Peri-launch/ post-launch
• Continuous follow-up of patients through a quality register
• Cost of all prescriptions for patients not registered in quality register devolved to the prescribing unit
(ii) Stockholm County Council
Pre-launch
• Extensive pre-launch activities including a critical evaluation for each approved indication
• Key messages from these activities broadcasted both to the public and to prescribers through the DTC
website as well as the Swedish Medical Journal
• Appreciable number of pre-launch meetings and training sessions with all major physician groups
around the key issues and concerns with dabigatran as well as its likely place in care. This included
meetings of the “Wise List forum”
• Production of educational folders regarding dabigatran, slide kits, published articles, and data on the
Janus website as well as published information for patients
• Forecasting the potential budget impact in 2011 and 2012 ahead of launch and monitoring this in practice
Peri-launch/ post-launch
• Development of a laboratory method to monitor dabigatran in plasma with LC-MS/MS technology
• Currently recommending sampling in the introductory phase to build a knowledge database. This to be
followed by more situation-based sampling to improve patient safety in the future
• Post-launch guidance in the “Wise List” with warfarin recommended as ﬁrst line treatment (education).
In addition, budget incentives to physicians in out-patient care with all drugs in the “Wise List” not
charged to their clinical budget in contrast with non-recommended drugs (economics)
Turkey Not reimbursed • Currently only reimbursed (75 mg) for prophylaxis in patients undergoing elective hip (maximum
35 days) or knee (maximum 10 days) replacement, and only reimbursed with special authorised reports
from orthopaedic surgeons (initial); subsequent follow-up prescriptions only reimbursed via orthopaedic
surgeons and subject to co-pay (enforcement)
• 110 and 150 mg currently not reimbursed (100% co-pay)
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